TIL Therapy hallway

Patient’s own immune cells effective as living drug for melanoma


A patient's own immune cells, expanded into an army of billions of immune cells in a specialized laboratory, can be used as a living drug against metastatic melanoma, an aggressive type of skin cancer, as the TIL trial has shown. The TIL trial, the world's first comparative phase 3 trial in solid tumors in general, is looking into the effect of T cell therapy in melanoma. Now that the results have been published in The New England Journal of Medicine (NEJM), the Dutch National Health Care Institute will assess whether TIL therapy could become a standard treatment, meaning that it will be incorporated into the basic health insurance package.

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.